Barclays’s TuHURA Biosciences HURA Stock Holding History

Barclays’s Portfolio HURA Stock Details HURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.5K	Buy	25,421 +16,180	+175%	+$37.7K	﹤0.01%	4261
2026 Q1	$16.5K	Sell	9,241 -43,374	-82%	-$53.2K	﹤0.01%	4611
2025 Q4	$39.8K	Buy	52,615 +15,725	+43%	+$30.1K	﹤0.01%	4774
2025 Q3	$91.5K	Sell	36,890 -11,394	-24%	-$30K	﹤0.01%	4641
2025 Q2	$108K	Buy	+48,284	New	+$163K	﹤0.01%	4549
2020 Q3	–	Sell	-21	Closed	-$25K	–	5653
2020 Q2	$25K	Sell	21 -30	-59%	-$38.4K	﹤0.01%	5153
2020 Q1	$36K	Hold	51	–	–	﹤0.01%	5405
2019 Q4	$62K	Buy	+51	New	+$55K	﹤0.01%	5680
2019 Q2	–	Sell	-4	Closed	-$35K	–	7341
2019 Q1	$35K	Buy	4 +1	+33%	+$6.79K	﹤0.01%	6108
2018 Q4	$17K	Buy	+3	New	+$29.1K	﹤0.01%	5980

Other funds holding HURA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Barclays's HURA Position: Q2 2026 in Review

Barclays increased its TuHURA Biosciences (HURA) stake by 175% in Q2 2026, buying an estimated $37.7K and bringing the position to 25,421 shares worth $59.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4261.

Barclays first reported a position in HURA in Q4 2018 and has held it in 10 quarters since. The position peaked at $108K in Q2 2025. 90 funds tracked by Wall St. Rank hold HURA as of Q2 2026.

Barclays held 25,421 shares of TuHURA Biosciences worth $59.5K as of Q2 2026.
Barclays bought 16,180 TuHURA Biosciences shares in Q2 2026, an estimated $37.7K.
TuHURA Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4261 holding.
Barclays first reported a position in TuHURA Biosciences in Q4 2018 and has held it in 10 quarters since.
Barclays's TuHURA Biosciences position peaked at $108K in Q2 2025.
90 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.